World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
100
Citations
37292
World Ranking
8261
National Ranking
118

Anna Sureda publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Anna Sureda sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 776 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Anna Sureda D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Anna Sureda sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 100 D-Index — 60th percentile

60% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Anna Sureda is affiliated with the Autonomous University of Barcelona in Spain and has an extensive publication record in the field of medicine, with a specific focus on oncology, hematology, and related subfields. Their research contributions include 917 publications in medicine, with notable emphasis on oncology (282 publications), hematology (162), pathology and forensic medicine (157), molecular biology (83), and genetics (73).

Sureda's main research topics cover a range of hematological malignancies and therapies, including:

  • CAR-T cell therapy research
  • Lymphoma diagnosis and treatment
  • Multiple myeloma research and treatments
  • Chronic lymphocytic leukemia research
  • Hematopoietic stem cell transplantation
  • Monoclonal and polyclonal antibodies research
  • Protein degradation and inhibitors

The scientist's recent papers include:

  • "Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma" (2021), New England Journal of Medicine
  • "Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma" (2022), New England Journal of Medicine
  • "Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma" (2021), New England Journal of Medicine
  • "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma" (2023), New England Journal of Medicine
  • "Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial" (2021), Journal of Clinical Oncology

Sureda frequently publishes in the following venues:

  • Blood (93 publications)
  • Clinical Lymphoma Myeloma & Leukemia (40 publications)
  • Bone Marrow Transplantation (39 publications)
  • Hematological Oncology (38 publications)
  • Journal of Clinical Oncology (21 publications)

Their collaboration network includes frequent co-authors such as Alberto Mussetti (62 joint publications), Albert Oriol (56), María-Victoria Mateos (49), Joaquin Martínez-López (47), and Jesús F. San Miguel (46).

Best Publications

  • Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

    Craig H. Moskowitz;Auayporn Nademanee;Tamas Masszi;Edward Agura

  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Steven Horwitz;Owen A O'Connor;Barbara Pro;Tim Illidge

  • Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually

    Jakob Passweg;H. Baldomero;P. Bader;Chiara Bonini

  • Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation

    BB Bjorkstrand;P Ljungman;H Svensson;J Hermans

  • Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation.

    Bruno Paiva;Maria-Belén Vidriales;Jorge Cerveró;Gema Mateo

  • Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009.

    P. Ljungman;M. Bregni;M. Brune;J. Cornelissen

  • Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015

    A. Sureda;P. Bader;S. Cesaro;P. Dreger

  • Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

    Anna Sureda;Stephen Robinson;Carmen Canals;Angelo M. Carella

  • Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis.

    Alois Gratwohl;Martin Stern;Ronald Brand;Jane Apperley

  • Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

    Juan José Lahuerta;Maria Victoria Mateos;Joaquin Martínez-López;Laura Rosiñol

  • Prophylaxis and treatment of GVHD: EBMT–ELN working group recommendations for a standardized practice

    T. Ruutu;A. Gratwohl;T. De Witte;B. Afanasyev

  • High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

    Bruno Paiva;Norma C. Gutiérrez;Laura Rosiñol;María-Belén Vídriales

  • Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

    Martin Hutchings;Franck Morschhauser;Gloria Iacoboni;Carmelo Carlo-Stella

  • A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma.

    Laura Rosiñol;José Antonio Pérez-Simón;Anna Sureda;Javier de la Rubia

  • Autologous Stem-Cell Transplantation for Hodgkin’s Disease: Results and Prognostic Factors in 494 Patients From the Grupo Español de Linfomas/Transplante Autólogo de Médula Ósea Spanish Cooperative Group

    A Sureda;R Arranz;A Iriondo;E Carreras

  • Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    S. K. Kumar;M. A. Dimopoulos;E. Kastritis;E. Terpos

  • Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study

    Anas Younes;Anna Sureda;Dina Ben-Yehuda;Pier Luigi Zinzani

  • Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases

    Ramón García‐Sanz;Silvia Montoto;Agustín Torrequebrada;Alfonso García De Coca

  • Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.

    Abraham S. Kanate;Alberto Mussetti;Mohamed A. Kharfan-Dabaja;Kwang W. Ahn;Kwang W. Ahn

  • Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe

    A. Urbano-Ispizua;N. Schmitz;T.J.M. de Witte;F. Frassoni

Frequent Co-Authors

Rodrigo Martino
Rodrigo Martino Hospital de Sant Pau
Juan José Lahuerta
Juan José Lahuerta Complutense University of Madrid
Joan Bladé
Joan Bladé University of Barcelona
Jesús F. San Miguel
Jesús F. San Miguel University of Navarra
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Norbert Schmitz
Norbert Schmitz University of Münster
Albert Oriol
Albert Oriol Autonomous University of Barcelona
Arnon Nagler
Arnon Nagler Sheba Medical Center
Dietger Niederwieser
Dietger Niederwieser Leipzig University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

As the demand for qualified healthcare professionals continues to grow, online degree programs provide flexible pathways into the medical field. Prospective students interested in studying medicine in the USA can explore a range of related online degrees that are both accessible and affordable.

For those aiming to become advanced practice nurses, there are cheap online fnp programs that combine quality education with cost-effectiveness. Additionally, prospective registered nurses or students seeking to advance from an associate to a bachelor’s degree can consider online nursing programs and the cheapest online rn to bsn programs to further their careers.

For nurses aspiring to reach leadership, research, or academic roles, the cheapest phd nursing programs online offer flexible options that allow continued employment while advancing academically. These pathways not only make career progression more accessible, but they also help address healthcare workforce shortages nationwide.

Best Scientists Citing Anna Sureda

Trending Scientists

Recently Published Articles